Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2021-02-10 AGM Information
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i Vicore Pharma Holding AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Vicore Pharma Holding AB (publ)'. It details the procedures for an upcoming Extraordinary General Meeting (EGM) scheduled for March 5, 2021, including voting by mail due to COVID-19, prerequisites for participation, and the proposed agenda items. The agenda includes the election of a chairman, approval of the agenda, and a key resolution regarding the approval of a directed new share issue (nyemission). This content is characteristic of materials sent to shareholders to inform them about a meeting and solicit their votes, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it relates to a general meeting, it is the notice/solicitation document itself, not the final voting results (DVA) or the AGM presentation materials (AGM-R).
2021-02-10 Swedish
Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 98% confidence The document is explicitly titled "Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)". It details the procedures for an extraordinary general meeting (EGM), including how shareholders can participate via advance voting due to COVID-19 restrictions. It outlines the proposed agenda items, which include the election of a chairman and a resolution regarding a directed issue of new shares. This content directly relates to the formal process and materials surrounding a shareholder meeting, specifically an EGM, which falls under the scope of AGM Information (AGM-R), even though it is an 'extraordinary' meeting rather than the standard 'annual' one, as it concerns meeting logistics and resolutions presented to shareholders. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2021-02-10 English
Vicore Pharma har genomfört en riktad nyemission om 336 miljoner kronor
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Vicore Pharma announcing the successful completion of a directed share issue (nyemission) of 336 million SEK. It details the number of shares issued, the subscription price, the purpose of the capital raise, and the lock-up periods. This falls under the category of announcements regarding new share issues or capital changes.
2021-02-10 Swedish
Vicore Pharma has completed a directed share issue of SEK 336 million
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the completion of a directed share issue (a capital raise) by Vicore Pharma. It details the number of shares issued, the subscription price, the use of proceeds, and the lock-up agreements. While it mentions an upcoming Extraordinary General Meeting, the primary purpose of the document is to announce the successful completion of a financing transaction. Therefore, it falls under the 'Capital/Financing Update' category.
2021-02-10 English
Vicore Pharma avser att genomföra en riktad nyemission
Capital/Financing Update Classification · 98% confidence The document is a press release from Vicore Pharma Holding AB announcing its intention to conduct a 'riktad nyemission' (directed new share issue) to institutional investors for approximately 300 million SEK via an accelerated bookbuilding procedure. This action involves raising capital through the issuance of new shares, which directly corresponds to the definition of a Capital/Financing Update. The document details the purpose of the funds (Phase III study, manufacturing, IPF franchise strengthening) and the process (bookbuilding, expected shareholder vote). This clearly falls under the 'Capital/Financing Update' category (CAP), rather than a general Regulatory Filing (RNS) or a Share Issue announcement (SHA), as it is a specific announcement about a financing event being planned/executed.
2021-02-09 Swedish
Vicore Pharma intends to carry out a directed share issue
Capital/Financing Update Classification · 99% confidence The document is a press release dated February 9, 2021, announcing that Vicore Pharma Holding AB intends to carry out a 'directed share issue' corresponding to approximately SEK 300 million through an accelerated bookbuilding procedure. This action involves raising capital through the issuance of new shares, which directly relates to the company's capital structure and financing activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific financing event.
2021-02-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.